Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor
Go back to Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thor| (NASDAQ: SVRA) | Delayed: 5.69 +0.19 (3.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.50 | 52 Week High | $ | |||
| Open | $5.59 | 52 Week Low | $ | |||
| Day High | $5.79 | P/E | N/A | |||
| Day Low | $5.50 | EPS | $ | |||
| Volume | 2,290,385 | |||||
